NC
FATE icon

NinePointTwo Capital’s Fate Therapeutics FATE Stock Holding History

NinePointTwo Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-49,325
Closed -$281K – 278
2023
Q1 		$281K Buy
49,325
+36,729
+292% +$222K 0.11% 55
2022
Q4 		$127K Buy
+12,596
New +$237K 0.05% 166

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

NinePointTwo Capital's FATE Position: Q2 2023 in Review

NinePointTwo Capital sold out of Fate Therapeutics (FATE) in Q2 2023, closing a stake of 49,325 shares — an estimated $281K sold.

NinePointTwo Capital first reported a position in FATE in Q4 2022 and held it in 2 quarters. The position peaked at $281K in Q1 2023. 188 funds tracked by Wall St. Rank hold FATE as of Q2 2023.

  • NinePointTwo Capital reported no remaining Fate Therapeutics position as of Q2 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 49,325 Fate Therapeutics shares in Q2 2023, an estimated $281K.
  • NinePointTwo Capital first reported a position in Fate Therapeutics in Q4 2022 and held it in 2 quarters.
  • NinePointTwo Capital's Fate Therapeutics position peaked at $281K in Q1 2023.
  • 188 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2023.

Based on NinePointTwo Capital's 13F filing for Q2 2023, filed 14 Aug 2023.